Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.

Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K

Open source

DOI: 10.3324/haematol.2022.280996
Published: 2023 Mar 1
Container: Haematologica
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2022.280996,
  title = {Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.},
  author = {Rai S and Kim WS and Ando K and Choi I and Izutsu K and Tsukamoto N and Yokoyama M and Tsukasaki K and Kuroda J and Ando J and Hidaka M and Koh Y and Shibayama H and Uchida T and Yang DH and Ishitsuka K and Ishizawa K and Kim JS and Lee HG and Minami H and Eom HS and Kurosawa M and Lee JH and Lee JS and Lee WS and Nagai H and Shindo T and Yoon DH and Yoshida S and Gillings M and Onogi H and Tobinai K},
  year = {2023},
  journal = {Haematologica},
  doi = {10.3324/haematol.2022.280996},
  url = {https://doi.org/10.3324/haematol.2022.280996}
}

RIS

TY  - JOUR
TI  - Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
AU  - Rai S
AU  - Kim WS
AU  - Ando K
AU  - Choi I
AU  - Izutsu K
AU  - Tsukamoto N
AU  - Yokoyama M
AU  - Tsukasaki K
AU  - Kuroda J
AU  - Ando J
AU  - Hidaka M
AU  - Koh Y
AU  - Shibayama H
AU  - Uchida T
AU  - Yang DH
AU  - Ishitsuka K
AU  - Ishizawa K
AU  - Kim JS
AU  - Lee HG
AU  - Minami H
AU  - Eom HS
AU  - Kurosawa M
AU  - Lee JH
AU  - Lee JS
AU  - Lee WS
AU  - Nagai H
AU  - Shindo T
AU  - Yoon DH
AU  - Yoshida S
AU  - Gillings M
AU  - Onogi H
AU  - Tobinai K
PY  - 2023
JO  - Haematologica
DO  - 10.3324/haematol.2022.280996
UR  - https://doi.org/10.3324/haematol.2022.280996
ER  -

APA

S, R., WS, K., K, A., I, C., K, I., N, T., M, Y., K, T., J, K., J, A., M, H., Y, K., H, S., T, U., DH, Y., K, I., K, I., JS, K., HG, L., H, M., HS, E., M, K., JH, L., JS, L., WS, L., H, N., T, S., DH, Y., S, Y., M, G., H, O., & K, T. (2023). Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.. Haematologica. https://doi.org/10.3324/haematol.2022.280996

Source records

pubmed · retrieved 2026-09-25T17:33:32.250Z